Clinical trial NCT03809286: The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder
Official title: The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Alcohol Use Disorder
Keywords: rTMS
alcohol use disorder
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2019-01-18
Enrollment: 44
Sex: ALL
Minimum age (years): 22
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: active vs. sham stimulation
Primary purpose: TREATMENT

Brief summary: The goal of this study is to investigate a treatment approach for alcohol use disorder (AUD) using a novel form of brain stimulation called deep repetitive transcranial magnetic stimulation (rTMS). The investigators will be targeting frontal regions of the brain that are important for memory and decision making. These brain regions have been shown to be impaired in patients with AUD. Previous studies have mostly used rTMS to a different frontal brain region that is not as deep. These studies have shown that rTMS can reduce craving for alcohol, but there is a lack of research showing that rTMS impacts alcohol consumption.

Detailed description: This study aims to examine the effect of rTMS on alcohol drinking behavior in an observed laboratory setting. Participants with AUD will be recruited and admitted to the inpatient unit for the whole study. After a brief detoxification period, they will receive 3 weeks of rTMS while in the research unit. Before and after the 3 weeks of stimulation, participants will participate in a decision-making experiment where they can choose to have an alcoholic drink or the equivalent amount of money that the drink would cost (alcohol self-administration sessions). The investigators will examine their response to alcohol, as well as their performance on tasks that relate to impulsivity and memory. Participants will also undergo an MRI scan (with spectroscopy) before and after the stimulation period to look at changes in the medial prefrontal cortex of the brain. Participants will then meet with a study physician for 6 weeks after the study for assessments of alcohol use and medical management sessions.

Eligibility criteria: Inclusion Criteria:

1. Current moderate to severe alcohol use disorder, per DSM-5
2. Use of alcohol which parallels or exceeds the amount alcohol that will be administered in this study (1 drinking episode per week raising BAL to 0.03 g/dl - approximately 2 drinks within an hour).
3. Age 22-55
4. Able to give informed consent, and comply with study procedures
5. Medically healthy, with the absence of current or past medical or neurological illnesses (including glaucoma, increased intracranial pressure, liver disease, cardiac disease, or seizure disorders)

Exclusion Criteria:

1. Has a contraindication to MRI, such as magnetically reactive implants, which includes metal in head except in mouth (cochlear implant, implanted brain stimulators, aneurysm clips), cardiac pacemakers, implanted neurostimulators and medication pumps, and intracardiac lines.
2. Substance use disorder with substances other than alcohol or nicotine. The current use of sedative-hypnotics or opiates will be exclusionary
3. Meets DSM-5 criteria for other psychiatric illness, such as major depression, that would interfere with participation.
4. History of seizures of any type
5. A family history of epilepsy
6. Taking psychotropic medication that would affect resting motor threshold (such as anticonvulsants) or increase risk of seizure (especially tricyclic antidepressants of neuroleptics)
7. Current suicide risk or a history of suicide attempt within the past 2 years
8. Have unstable physical disorders, including those that are previously undiagnosed, untreated, inadequately treated, or active to an extent which might make participation hazardous. For example, hypertension (a resting blood pressure \> 140/90), heart failure, a recent history of myocardial infarction, previous stroke, brain lesions, any history of seizures under any circumstances or low hemoglobin.
9. Currently pregnant
10. History of severe alcohol withdrawal requiring medical care, such as withdrawal seizures, delirium tremens, withdrawal necessitating medical detoxification.
11. A desire to pursue standard treatment for AUD, such as a rehabilitation program or FDA approved medications for AUD

Primary outcomes:
measure: Change in the choice to self-administer alcohol in the laboratory as assessed by counting the number of drinks consumed in the 2-hour laboratory session.
timeFrame: 4 weeks
measure: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0.
timeFrame: 10 weeks
Secondary outcomes:
measure: Change in craving for alcohol measured using the Alcohol Urge Questionnaire (AUQ).
timeFrame: 4 weeks
measure: Change in GABA in the mPFC and ACC as measured with magnetic resonance spectroscopy (MRS).
timeFrame: 4 weeks
measure: Change in abstinence from alcohol following discharge assessed with the Time Line Follow Back Interview.
timeFrame: 10 weeks
measure: Changes in cognitive control as measured by using the Frontal Assessment Battery (FAB).
timeFrame: 4 weeks
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
affiliation: New York State Psychiatric Institute
name: Jonathan Wai
role: PRINCIPAL_INVESTIGATOR
References: